Molecular

Molecular Partners is a clinical-stage biopharmaceutical company pioneering the development of DARPin therapeutics, a novel class of custom-built protein drugs. The company's proprietary DARPin platform enables the creation of multi-specific therapies designed to overcome the limitations of conventional antibodies, particularly in oncology and ophthalmology. Their lead programs include radioligand therapies and T-cell engagers that target specific tumor antigens with high affinity and stability. Molecular Partners maintains strategic collaborations with major pharmaceutical companies like Novartis and AbbVie to advance its diverse pipeline of next-generation biologics.